Explore the latest in opioid use disorders, including recent advances in opioid rehabilitation programs, treatments, and public health interventions.
This cohort study evaluates the association between hospitals attesting to an opioid use disorder (OUD) emergency department (ED) treatment pathway and patients’ initiation of buprenorphine treatment.
This cross-sectional study characterizes factors associated with the direct addition of buprenorphine to urine specimens in individuals prescribed buprenorphine for opioid use disorder.
This cohort study examines the risk for opioid overdose associated with the presence of opioids within the household.
This time-series analysis assesses the association of implementation of postoverdose outreach programs with opioid fatality rates in Massachusetts municipalities with high numbers of opioid-related medical emergency services responses.
This randomized clinical trial compares the effect of abstinence incentives combined with either bupropion slow release or placebo on cocaine abstinence outcomes among individuals receiving methadone treatment for opioid use disorder.
This viewpoint discusses and suggests clinical interventions to be implemented by clinicians and health systems in North America to reduce opioid overdose deaths among at-risk patients.
This cohort study involves assessing causes of death among people experiencing homelessness in Boston from 2003 to 2018.
This cross-sectional study of a multistate sample of electronic health record data examines the association between primary care visit length and potentially inappropriate prescribing.
This case-control study examines the use and quality of treatment for opioid use disorder in adults with diagnosed disabling conditions, compared with adults without these diagnoses.
In this Viewpoint, officials from the White House Office of National Drug Control Policy describe 3 actions that health care personnel can take to expand prevention and treatment of substance misuse and overdose.
This Viewpoint discusses the goals of the inaugural National Drug Control Strategy, which as the ambitious agenda of emphasizing harm reduction practices, medications for treating opioid use disorder, and criminal justice reform, as well as supporting long-term recovery and interrupting illicit drug trafficking.
This study examines the available data used to surveil state-level drug overdoses and characterizes them based on their timeliness, drug involvement, and specification of nonfatal outcomes.
This interrupted time-series analysis uses data from the National Inpatient Sample and the Acute Liver Failure Study Group to assess the odds of hospitalization and the proportion of acute liver failure cases with acetaminophen and opioid toxicity prior to and after the US Food and Drug Administration mandate to limit acetaminophen (paracetamol) to 325 mg/tablet in combination acetaminophen and opioid medications.
This cohort study examines buprenorphine treatment initiation, response, and follow-up among patients presenting to California emergency departments (EDs) who reported fentanyl or other opioid use.
This quality improvement study involves comparison of opioid prescription data before and after implementation of an opioid stewardship program in a safety-net medical system.
This Viewpoint discusses opioid pain agreements to promote patient-centered care.
This cross-sectional study evaluates trends in out-of-pocket costs for and characteristics of pharmacy-dispensed buprenorphine medications for opioid use disorder treatment by type of payer from 2015 to 2020.
This cohort study assesses a protocol for eliminating postdischarge opioid prescriptions after major urologic cancer surgery by assessing patients who receive usual, reduced, or no opioids.
This cohort study examines outcomes associated with tapering of opioid therapy in patients who have received stable doses for 1 year, including subcohorts of those with hypertension or diabetes.
Customize your JAMA Network experience by selecting one or more topics from the list below.